GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

National Science Foundation

GRI Bio, Inc.

Our CEO, Dr. Marc Hertz, highlights our novel approach to #immunemodulation. Watch the full video here: https://bit.ly/3FvbDJn  

#NKT #AutoimmuneDisease #InflammatoryDisease #FibroticDisease

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/3GvZu7M 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

Access our library of scientific publications for a comprehensive review of our data. https://bit.ly/3OhuOf8  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

#WhatThisMeans: Drs. Marc Hertz and Al Agro, CEO and CMO of GRI Bio, Inc., highlight the Company’s recent IND clearance for lead program targeting #idiopathicpulmonaryfibrosis. 

https://lnkd.in/eUEkB7DC
#IPF #NKT #FibroticDisease

GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant #NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/47we2Qm 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

We hope your Thanksgiving table is full of your favorite food and surrounded by your favorite people.

Regulating #NKT cells is a selective approach to #immunomodulation via resetting the immune response. Learn more here: https://bit.ly/3pRUJAu  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

GRI Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update.

https://bit.ly/47ce5kt 
#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

Email alerts make it easy to stay up to date! Sign up here: https://bit.ly/45GwuVq  

#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

We are dedicated to advancing new therapies through innovative approaches for the treatment of #inflammatory, #fibrotic and #autoimmune diseases. 

#NKT

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		100K -
cost of revenue	735 -		73K -	206K 182.19%	57K 72.33%
gross profit	-735 -	100K 13,705.44%	-73K 173%	-206K 182.19%	-57K 72.33%
selling and marketing expenses
general and administrative expenses			813K -	2.00M 145.63%
selling general and administrative expenses	1.27M -	1.11M 13.00%	813K 26.49%	2.00M 145.63%	8.10M 305.51%
research and development expenses	1.88M -	3.71M 96.93%	249K 93.28%	242K 2.81%	3.23M 1,235.54%
other expenses
cost and expenses	3.15M -	4.89M 54.96%	1.06M 78.27%	2.24M 110.83%	11.39M 408.58%
operating expenses	3.15M -	4.81M 52.62%	1.06M 77.93%	2.24M 110.83%	11.33M 406.03%
interest expense	197.03K -	34K 82.74%	547K 1,508.82%	653K 19.38%	2.08M 218.84%
ebitda	-3.15M -	-4.71M 49.44%	-1.01M 78.51%	-2.19M 116.09%	-11.33M 417.59%
operating income	-3.15M -	-4.79M 51.79%	-1.06M 77.82%	-2.24M 110.83%	-11.39M 408.58%
depreciation and amortization	735 -	75K 10,104.08%	49K 34.67%	50K 2.04%	57K 14.00%
total other income expenses net	-310.07K -	-34K 89.03%	-497K 1,361.76%	-978K 96.78%	-1.65M 68.71%
income before tax	-3.46M -	-4.82M 39.18%	-1.56M 67.67%	-3.22M 106.35%	-13.04M 305.25%
income tax expense	5 -		-50K -	325K 750%
net income	-3.46M -	-4.82M 39.18%	-1.51M 68.71%	-3.54M 134.72%	-13.04M 268.07%
weighted average shs out	32.43K -	32.43K 0%	32.44K 0.03%	4.30K 86.75%	461.57K 10,634.58%
weighted average shs out dil	32.43K -	32.43K 0%	32.44K 0.03%	4.30K 86.75%	461.57K 10,634.58%
eps	-106.82 -	-148.68 39.19%	-46.51 68.72%	-823.76 1,671.15%	-28.25 96.57%
epsdiluted	-106.82 -	-148.68 39.19%	-46.51 68.72%	-823.76 1,671.15%	-28.25 96.57%

COM:GRIBIO

GRI Bio, Inc.

Last Close

1.27

26/07 20:00

Market Cap

1.59M

Beta: -

Volume Today

457.28K

Avg: -

Preview